{"pmid":32333025,"title":"Characteristics of COVID-19 pandemic and public health consequences.","text":["Characteristics of COVID-19 pandemic and public health consequences.","Herz","Stang, Andreas","Standl, Fabian","Jockel, Karl-Heinz","32333025"],"journal":"Herz","authors":["Stang, Andreas","Standl, Fabian","Jockel, Karl-Heinz"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333025","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s00059-020-04932-0","source":"PubMed","topics":["Diagnosis","Prevention","Treatment"],"weight":1,"_version_":1665071049685860353,"score":8.518259,"similar":[{"pmid":32093211,"pmcid":"PMC7074453","title":"Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China.","text":["Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China.","In December 2019, cases of unidentified pneumonia with a history of exposure in the Huanan Seafood Market were reported in Wuhan, Hubei Province. A novel coronavirus, SARS-CoV-2, was identified to be accountable for this disease. Human-to-human transmission is confirmed, and this disease (named COVID-19 by World Health Organization (WHO)) spread rapidly around the country and the world. As of 18 February 2020, the number of confirmed cases had reached 75,199 with 2009 fatalities. The COVID-19 resulted in a much lower case-fatality rate (about 2.67%) among the confirmed cases, compared with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain. The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis. The source of the virus and the pathogenesis of this disease are still unconfirmed. No specific therapeutic drug has been found. The Chinese Government has initiated a level-1 public health response to prevent the spread of the disease. Meanwhile, it is also crucial to speed up the development of vaccines and drugs for treatment, which will enable us to defeat COVID-19 as soon as possible.","J Clin Med","Deng, Sheng-Qun","Peng, Hong-Juan","32093211"],"abstract":["In December 2019, cases of unidentified pneumonia with a history of exposure in the Huanan Seafood Market were reported in Wuhan, Hubei Province. A novel coronavirus, SARS-CoV-2, was identified to be accountable for this disease. Human-to-human transmission is confirmed, and this disease (named COVID-19 by World Health Organization (WHO)) spread rapidly around the country and the world. As of 18 February 2020, the number of confirmed cases had reached 75,199 with 2009 fatalities. The COVID-19 resulted in a much lower case-fatality rate (about 2.67%) among the confirmed cases, compared with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain. The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis. The source of the virus and the pathogenesis of this disease are still unconfirmed. No specific therapeutic drug has been found. The Chinese Government has initiated a level-1 public health response to prevent the spread of the disease. Meanwhile, it is also crucial to speed up the development of vaccines and drugs for treatment, which will enable us to defeat COVID-19 as soon as possible."],"journal":"J Clin Med","authors":["Deng, Sheng-Qun","Peng, Hong-Juan"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32093211","week":"20209|Feb 24 - Mar 01","doi":"10.3390/jcm9020575","keywords":["2019-ncov","covid-19","sars-cov-2","clinical characteristics","coronavirus","diagnosis","pneumonia","prevention and control","public health","treatment"],"source":"PubMed","topics":["Treatment","Prevention","Mechanism","Diagnosis"],"weight":1,"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875175608323,"score":66.28762},{"pmid":32300496,"pmcid":"PMC7158591","title":"Coronavirus Disease: A Review of a New Threat to Public Health.","text":["Coronavirus Disease: A Review of a New Threat to Public Health.","In December 2019, several patients from Wuhan, China were admitted to hospitals with symptoms of pneumonia. As the number of patients presenting with similar symptoms started to rise, the causative agent was eventually isolated from samples. It was initially called the 2019 novel coronavirus (2019-nCoV) and has been recently relabelled as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); the disease it causes has been named coronavirus disease 2019 (COVID-19). Over the next few weeks, the virus spread from Wuhan to affect different provinces in China and, after a few months, it is now present in 109 countries. As of March 10, 2020, there have been 113,702 confirmed cases globally, and 4,012 deaths have been registered. The World Health Organization (WHO) called COVID-19 a pandemic on March 11, 2020. There are multiple drug trials going on with some positive results. However, since no vaccine is available, the best way to combat the virus is by preventive methods.","Cureus","Ramphul, Kamleshun","Mejias, Stephanie G","32300496"],"abstract":["In December 2019, several patients from Wuhan, China were admitted to hospitals with symptoms of pneumonia. As the number of patients presenting with similar symptoms started to rise, the causative agent was eventually isolated from samples. It was initially called the 2019 novel coronavirus (2019-nCoV) and has been recently relabelled as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); the disease it causes has been named coronavirus disease 2019 (COVID-19). Over the next few weeks, the virus spread from Wuhan to affect different provinces in China and, after a few months, it is now present in 109 countries. As of March 10, 2020, there have been 113,702 confirmed cases globally, and 4,012 deaths have been registered. The World Health Organization (WHO) called COVID-19 a pandemic on March 11, 2020. There are multiple drug trials going on with some positive results. However, since no vaccine is available, the best way to combat the virus is by preventive methods."],"journal":"Cureus","authors":["Ramphul, Kamleshun","Mejias, Stephanie G"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300496","week":"202016|Apr 13 - Apr 19","doi":"10.7759/cureus.7276","keywords":["coronavirus disease","covid-19","sars-cov-2","severe acute respiratory syndrome coronavirus 2","wuhan"],"source":"PubMed","topics":["Prevention","Diagnosis","Treatment"],"weight":1,"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664635401176875008,"score":55.054363},{"pmid":32113507,"pmcid":"PMC7133597","title":"Lessons for managing high-consequence infections from first COVID-19 cases in the UK.","text":["Lessons for managing high-consequence infections from first COVID-19 cases in the UK.","Lancet","Moss, Peter","Barlow, Gavin","Easom, Nicholas","Lillie, Patrick","Samson, Anda","32113507"],"journal":"Lancet","authors":["Moss, Peter","Barlow, Gavin","Easom, Nicholas","Lillie, Patrick","Samson, Anda"],"date":"2020-03-02T11:00:00Z","year":2020,"_id":"32113507","week":"202010|Mar 02 - Mar 08","doi":"10.1016/S0140-6736(20)30463-3","source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"locations":["GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"_version_":1664640875069702147,"score":53.769806},{"pmid":32202824,"title":"The novel coronavirus (COVID-2019) outbreak: Amplification of public health consequences by media exposure.","text":["The novel coronavirus (COVID-2019) outbreak: Amplification of public health consequences by media exposure.","The 2019 novel coronavirus (COVID-2019) has led to a serious outbreak of often severe respiratory disease, which originated in China and has quickly become a global pandemic, with far-reaching consequences that are unprecedented in the modern era. As public health officials seek to contain the virus and mitigate the deleterious effects on worldwide population health, a related threat has emerged: global media exposure to the crisis. We review research suggesting that repeated media exposure to community crisis can lead to increased anxiety, heightened stress responses that can lead to downstream effects on health, and misplaced health-protective and help-seeking behaviors that can overburden health care facilities and tax available resources. We draw from work on previous public health crises (i.e., Ebola and H1N1 outbreaks) and other collective trauma (e.g., terrorist attacks) where media coverage of events had unintended consequences for those at relatively low risk for direct exposure, leading to potentially severe public health repercussions. We conclude with recommendations for individuals, researchers, and public health officials with respect to receiving and providing effective communications during a public health crisis. (PsycInfo Database Record (c) 2020 APA, all rights reserved).","Health Psychol","Garfin, Dana Rose","Silver, Roxane Cohen","Holman, E Alison","32202824"],"abstract":["The 2019 novel coronavirus (COVID-2019) has led to a serious outbreak of often severe respiratory disease, which originated in China and has quickly become a global pandemic, with far-reaching consequences that are unprecedented in the modern era. As public health officials seek to contain the virus and mitigate the deleterious effects on worldwide population health, a related threat has emerged: global media exposure to the crisis. We review research suggesting that repeated media exposure to community crisis can lead to increased anxiety, heightened stress responses that can lead to downstream effects on health, and misplaced health-protective and help-seeking behaviors that can overburden health care facilities and tax available resources. We draw from work on previous public health crises (i.e., Ebola and H1N1 outbreaks) and other collective trauma (e.g., terrorist attacks) where media coverage of events had unintended consequences for those at relatively low risk for direct exposure, leading to potentially severe public health repercussions. We conclude with recommendations for individuals, researchers, and public health officials with respect to receiving and providing effective communications during a public health crisis. (PsycInfo Database Record (c) 2020 APA, all rights reserved)."],"journal":"Health Psychol","authors":["Garfin, Dana Rose","Silver, Roxane Cohen","Holman, E Alison"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32202824","week":"202013|Mar 23 - Mar 29","doi":"10.1037/hea0000875","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["China","Ebola"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664639760419782656,"score":52.07763},{"pmid":32228252,"title":"COVID-19, ACE2, and the cardiovascular consequences.","text":["COVID-19, ACE2, and the cardiovascular consequences.","The novel SARS coronavirus SARS-CoV-2 pandemic may be particularly deleterious to patients with underlying cardiovascular disease (CVD). The mechanism for SARS-CoV-2 infection is the requisite binding of the virus to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) and internalization of the complex by the host cell. Recognition that ACE2 is the coreceptor for the coronavirus has prompted new therapeutic approaches to block the enzyme or reduce its expression to prevent the cellular entry and SARS-CoV-2 infection in tissues that express ACE2 including lung, heart, kidney, brain, and gut. ACE2, however, is a key enzymatic component of the renin-angiotensin-aldosterone system (RAAS); ACE2 degrades ANG II, a peptide with multiple actions that promote CVD, and generates Ang-(1-7), which antagonizes the effects of ANG II. Moreover, experimental evidence suggests that RAAS blockade by ACE inhibitors, ANG II type 1 receptor antagonists, and mineralocorticoid antagonists, as well as statins, enhance ACE2 which, in part, contributes to the benefit of these regimens. In lieu of the fact that many older patients with hypertension or other CVDs are routinely treated with RAAS blockers and statins, new clinical concerns have developed regarding whether these patients are at greater risk for SARS-CoV-2 infection, whether RAAS and statin therapy should be discontinued, and the potential consequences of RAAS blockade to COVID-19-related pathologies such as acute and chronic respiratory disease. The current perspective critically examines the evidence for ACE2 regulation by RAAS blockade and statins, the cardiovascular benefits of ACE2, and whether ACE2 blockade is a viable approach to attenuate COVID-19.","Am J Physiol Heart Circ Physiol","South, Andrew M","Diz, Debra I","Chappell, Mark C","32228252"],"abstract":["The novel SARS coronavirus SARS-CoV-2 pandemic may be particularly deleterious to patients with underlying cardiovascular disease (CVD). The mechanism for SARS-CoV-2 infection is the requisite binding of the virus to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) and internalization of the complex by the host cell. Recognition that ACE2 is the coreceptor for the coronavirus has prompted new therapeutic approaches to block the enzyme or reduce its expression to prevent the cellular entry and SARS-CoV-2 infection in tissues that express ACE2 including lung, heart, kidney, brain, and gut. ACE2, however, is a key enzymatic component of the renin-angiotensin-aldosterone system (RAAS); ACE2 degrades ANG II, a peptide with multiple actions that promote CVD, and generates Ang-(1-7), which antagonizes the effects of ANG II. Moreover, experimental evidence suggests that RAAS blockade by ACE inhibitors, ANG II type 1 receptor antagonists, and mineralocorticoid antagonists, as well as statins, enhance ACE2 which, in part, contributes to the benefit of these regimens. In lieu of the fact that many older patients with hypertension or other CVDs are routinely treated with RAAS blockers and statins, new clinical concerns have developed regarding whether these patients are at greater risk for SARS-CoV-2 infection, whether RAAS and statin therapy should be discontinued, and the potential consequences of RAAS blockade to COVID-19-related pathologies such as acute and chronic respiratory disease. The current perspective critically examines the evidence for ACE2 regulation by RAAS blockade and statins, the cardiovascular benefits of ACE2, and whether ACE2 blockade is a viable approach to attenuate COVID-19."],"journal":"Am J Physiol Heart Circ Physiol","authors":["South, Andrew M","Diz, Debra I","Chappell, Mark C"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32228252","week":"202014|Mar 30 - Apr 05","doi":"10.1152/ajpheart.00217.2020","keywords":["ace2","ang ii","covid-19","sars-cov-2","renin-angiotensin system","statins"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Aldosterone"],"_version_":1664638455250944001,"score":47.268276}]}